Lacosamide Fresenius Kabi

Lacosamide, the active ingredient in Lacosamide Fresenius Kabi, is a sodium channel blocker presented as an injectable solution for intravenous use. It is used as adjunctive therapy for partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lacosamide is an antiepileptic drug that acts on neuronal sodium channels to control seizure activity. - Partial‑onset seizures: reduces seizure frequency when added to existing therapy. - Focal epilepsy: helps achieve better seizure control in patients with refractory focal seizures. - Adjunctive therapy for epilepsy: improves overall seizure management when combined with other antiepileptic medications.

Lacosamide may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of stomach upset or urge to vomit. - Headache: mild to moderate cranial pain. - Fatigue: increased tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, including atrial fibrillation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal ideation: thoughts of self‑harm or suicide. - Respiratory depression: slowed breathing requiring monitoring. - Anaphylaxis: severe allergic reaction with potential airway compromise. - Hepatotoxicity: liver enzyme elevations indicating possible liver injury.

When prescribing Lacosamide, clinicians should consider several safety aspects. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction: obtain baseline ECG and monitor for arrhythmias. - Concomitant antiepileptics: watch for additive CNS depression. - Pregnancy: safety data are limited; use only if benefit outweighs potential risk. - Store at room temperature: keep in original packaging, protect from moisture and light.

Lacosamide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine): may markedly reduce lacosamide levels. - Other sodium channel blockers: increase risk of central nervous system depression. - QT‑prolonging agents: may heighten the chance of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Oral contraceptives: lacosamide may decrease hormonal efficacy. - Valproate: may require dose adjustments due to altered plasma concentrations. - Alcohol: concurrent use can intensify dizziness and sedation.